Codiak BioSciences, Inc. Common Stock
CDAK
CDAK was delisted on the 4th of April, 2023.
1 hedge funds and large institutions have $0 invested in Codiak BioSciences, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 26 closing their positions.
96% less funds holding
Funds holding: 27 → 1 (-26)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $1.44M → $0 (-$1.44M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 26
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$618K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$351K |
| 3 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$148K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$101K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$78.3K |
CDAK Hedge Fund Activity: Q2 2023 in Review
1 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q2 2023, worth a combined $0 — down 100% from $1.44M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CDAK and 0 opened new positions — a net loss of 26 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Flagship Pioneering, exiting entirely with an estimated $618K sold.
- 1 institutional investor held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q2 2023, down from 27 in Q1 2023.
- Funds reported $0 of Codiak BioSciences, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q2 2023 and 26 closed out, a net change of -26 holders.
- The largest Codiak BioSciences, Inc. Common Stock seller in Q2 2023 was Flagship Pioneering, an estimated $618K sold.
Based on aggregated 13F filings for Q2 2023.